Baudax Bio (BXRX) Tops Q3 EPS by $1.36
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Baudax Bio Reports Third Quarter 2020 Financial Results
November 9, 2020 7:05 AM ESTANJESO® Launch Underway; Over 50 Institutions have Added ANJESO to Their Formularies with Users Giving Highly Positive Feedback and Average Monthly Orders Increasing over 125% Since Launch
Secured and Implemented Permanent J-Code for ANJESO from CMS October 1, Along with Two Major Group Purchasing Agreements with Vizient and Premier
Management to Host Investor Conference Call and Webcast Today at 9:00 a.m. ET
MALVERN, Pa., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for... More
